Table 2 |
|||
|
Demographic data and baseline characteristics of the patients |
|||
|
Characteristics |
Placebo (n = 23) |
100 mg/day 5-Loxin® (n = 24) |
250 mg/day 5-Loxin® (n = 23) |
|
|
|||
|
Sex (male/female; n) |
5/18 |
7/17 |
8/15 |
|
Age (years) |
52.43 ± 9.65 |
52.37 ± 8.37 |
53.22 ± 8.73 |
|
Body weight (kg) |
61.48 ± 10.69 |
61.08 ± 10.67 |
54.84 ± 10.19 |
|
Body mass index (kg/m2) |
26.05 ± 4.29 |
25.91 ± 4.94 |
22.64 ± 4.07 |
|
Visual analog score (mm) |
56.88 ± 12.04 |
57.05 ± 8.71 |
55.62 ± 9.26 |
|
Lequesne's Functional Index |
12.76 ± 2.6 |
12.1 ± 2.76 |
12.04 ± 3.03 |
|
WOMAC score |
|||
|
Pain subscale |
38.04 ± 9.7 |
48.08 ± 14.05 |
37.17 ± 13.8 |
|
Stiffness subscale |
33.15 ± 13.3 |
31.8 ± 17.6 |
27.7 ± 16.8 |
|
Function subscale |
41.3 ± 9.6 |
41.5 ± 11.1 |
38.6 ± 11.1 |
|
|
|||
|
Values are expressed as mean ± standard deviation. WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index. |
|||
|
Sengupta et al. Arthritis Research & Therapy 2008 10:R85 doi:10.1186/ar2461 |
|||
